MARKET

MCRB

MCRB

Seres Therapeutics Inc
NASDAQ
7.06
+0.53
+8.12%
After Hours: 7.16 +0.1 +1.42% 19:56 10/06 EDT
OPEN
6.53
PREV CLOSE
6.53
HIGH
7.16
LOW
6.53
VOLUME
679.21K
TURNOVER
0
52 WEEK HIGH
11.69
52 WEEK LOW
2.500
MARKET CAP
875.95M
P/E (TTM)
-6.1827
1D
5D
1M
3M
1Y
5Y
UNIT, ARCT and MCRB are among after hour movers
Gainers: Sharecare (SHCR) +8%. Allogene Therapeutics (<a hre...
Seekingalpha · 7h ago
U.S. FDA panel recommends Ferring's fecal transplant therapy
U.S. FDA panel recommends Ferring's fecal transplant therapy
Reuters · 09/22 20:25
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Benzinga · 09/20 12:15
Ford, Evotec And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
U.S. stock futures traded lower this morning after recording gains in the previous session. Here are some big stocks moving lower in today’s pre-market trading session.
Benzinga · 09/20 11:27
Why O2Micro International Is Trading Higher By 7%; Here Are 25 Stocks Moving Premarket
Gainers
Benzinga · 09/20 10:22
PTRA, MCRB and DADA are among after hour movers
Gainers: Wix (WIX) +6%. Backblaze (<a href="https://seekingalpha...
Seekingalpha · 09/16 21:19
Seres Therapeutics to Present at World Anti-Microbial Resistance Congress
CAMBRIDGE, Mass., September 08, 2022--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Matthew Henn, Ph.D., Chief Scientific Officer at Seres, will be presenting at the World Anti-Microbial Resistance...
Business Wire · 09/08 11:00
Why IMARA Jumped Around 75%; Here Are 54 Biggest Movers From Yesterday
Gainers
Benzinga · 09/08 09:26
More
About MCRB
Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The Company's lead product candidate, SER-109, is designed to reduce further recurrences of Clostridioides difficle infection (CDI). It is also developing therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. SER-155, a microbiome therapeutic candidate consisting of a consortium of cultivated bacteria, is designed to reduce incidences of gastrointestinal infections, bloodstream infections and graft versus host disease (GvHD) in patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). In addition, using its microbiome therapeutics platform, the Company is developing SER-287 and SER-301 to treat ulcerative colitis (UC).

Webull offers kinds of Seres Therapeutics Inc stock information, including NASDAQ:MCRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MCRB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MCRB stock methods without spending real money on the virtual paper trading platform.